<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9558">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05695417</url>
  </required_header>
  <id_info>
    <org_study_id>OTX-TKI-2022-101</org_study_id>
    <nct_id>NCT05695417</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy</brief_title>
  <official_title>A Phase 1B, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravitreal Injection in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocular Therapeutix, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects with Moderately Severe&#xD;
      to Severe Non-proliferative Diabetic Retinopathy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Safety,&#xD;
      Tolerability, and Efficacy of OTX-TKI (axitinib implant) for Intravitreal Injection in&#xD;
      Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2023</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Frequency of treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Best Corrected Visual Acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Best Corrected Visual Acuity (BCVA) changes from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central subfield thickness changes</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Central subfield thickness changes from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Therapy</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Proportion of subjects receiving rescue therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic Retinopathy Severity Scale (DRSS) changes</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Diabetic Retinopathy Severity Scale (DRSS) changes from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Non-proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>OTX-TKI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTX-TKI</intervention_name>
    <description>Injection of OTX-TKI</description>
    <arm_group_label>OTX-TKI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham Injection of OTX-TKI</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are at least 18 years of age or older&#xD;
&#xD;
          -  Moderately severe to severe NPDR in the study eye defined as: DRSS levels of 47 or 53&#xD;
             as determined by the reading center&#xD;
&#xD;
          -  Diabetes type 1 or 2&#xD;
&#xD;
          -  BCVA ETDRS letter score in the study eye of ≥69 letters (approximate Snellen&#xD;
             equivalent of 20/40 or better)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  DME within 6 months involving the center of the macula in the study eye&#xD;
&#xD;
          -  Presence of DME threatening the center (within 200 microns) of the macula in the study&#xD;
             eye&#xD;
&#xD;
          -  OCT CSFT of ≥320 μm in the study eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Project Manager</last_name>
    <phone>1-781-357-4000</phone>
    <email>clinicalaffairs@ocutx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Lemont</city>
        <state>Illinois</state>
        <zip>60439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutiux, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78750</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 5, 2023</study_first_submitted>
  <study_first_submitted_qc>January 12, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2023</study_first_posted>
  <last_update_submitted>March 2, 2023</last_update_submitted>
  <last_update_submitted_qc>March 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonproliferative diabetic retinopathy</keyword>
  <keyword>Diabetic retinopathy OTX-TKI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

